Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Summary

The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice

Eligibility

Inclusion Criteria:

Phase I: retrospective chart review

For inclusion in the study, participants must meet ALL of the following criteria:

* Are an adult aged 18 or over at baseline
* Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
* Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024
* Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)
* Are not enrolled in any interventional clinical trial at study baseline

Phase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey

Exclusion Criteria:

• None with the proviso that all inclusion criteria are met.

Conditions2

Interventions1

Related trials

• A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China — Bristol-Myers Squibb
• A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy — Bristol-Myers Squibb
• Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) — Bristol-Myers Squibb
• Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan — Bristol-Myers Squibb
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) — Bristol-Myers Squibb
• Real-world Patient Reported Outcomes Among Patients Treated With Camzyos — Bristol-Myers Squibb
• Mavacamten Pregnancy Surveillance Program — Bristol-Myers Squibb
• Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM — Michael Ayers

Browse More Trials